Investor relations
Corporate presentation
This section provides access to Solvonis Therapeutics plc’s latest corporate presentation, which summarises the Company’s strategy, pipeline, recent developments, and financial position. The presentation is intended to support institutional and private investors, analysts, and other stakeholders in understanding Solvonis’ business and its progress across addiction, psychiatry, and neurology.
Purpose of the presentation
The corporate presentation contains an overview of:
Solvonis’ mission, strategy, and business model
The Company’s R&D pipeline, including clinical and preclinical programmes
Key operational and scientific milestones
Market context and areas of unmet medical need
Corporate structure and governance
Recent corporate updates and upcoming priorities
The presentation is updated periodically. Investors should ensure they are viewing the most recent version by downloading the file directly from this page.
Use of information
The information contained in the corporate presentation is provided for general informational purposes only and does not constitute, and should not be construed as:
an offer to sell or issue securities,
a solicitation of an offer to purchase or subscribe for securities, or
a recommendation or inducement to engage in investment activity.
Nothing in the presentation is intended to form the basis of any investment decision and should not be relied upon for any purpose. Prospective investors should rely solely on information formally published by Solvonis Therapeutics plc via regulatory channels.
Forward-looking statements
The corporate presentation may include forward-looking statements, including statements related to Solvonis’ strategy, future operations, clinical development plans, regulatory pathways, market opportunities, and financial outlook. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.
Solvonis undertakes no obligation to update any forward-looking statements contained in the presentation except as required by applicable law or regulation.